Welcome to our dedicated page for NuSkin Enterprises news (Ticker: NUS), a resource for investors and traders seeking the latest updates and insights on NuSkin Enterprises stock.
Nu Skin Enterprises, Inc. (NYSE: NUS) is a global leader in health and beauty, founded 35 years ago. The company excels in creating and distributing innovative consumer products, focusing on beauty and wellness. Nu Skin’s product lines include personal care items under the Nu Skin brand and nutritional supplements marketed under the Pharmanex brand. Operating in more than 50 countries, the firm’s extensive reach reflects its robust international presence.
Nu Skin Enterprises encompasses several companies such as Nu Skin, Groviv, Wasatch Labs, Elevate Health Sciences, and Casepak. This diverse portfolio enables the company to offer a wide range of products and services, from consumer goods to advanced manufacturing and controlled environment agriculture technologies.
In recent developments, Nu Skin has shown a commitment to innovation and growth. In October 2023, the company announced the release of its third quarter financial results, revealing both challenges and growth opportunities. Despite economic hurdles, particularly in Mainland China and the Americas, Nu Skin experienced stabilization and growth in regions like Europe and Africa. The introduction of new products, such as the ageLOC® WellSpa iO™ and an upcoming mental wellness category in 2024, showcases the firm’s dedication to expanding its offerings and driving long-term success.
In November 2023, Nu Skin celebrated the opening of a new manufacturing facility in Shanghai, China, an investment of approximately $55 million. This facility exemplifies the company's commitment to enhancing production capacity and supply chain efficiency, particularly in Asian markets. The plant uses Industry 4.0 standards, featuring smart systems and real-time data analysis, further underlining Nu Skin’s focus on technological advancement and sustainability.
Additionally, in February 2024, Nu Skin introduced the RenuSpa iO, a smart device designed to promote skin health and body confidence. This FDA-cleared device embodies the latest in microcurrent technology, offering personalized beauty and wellness solutions. The Nu Skin Vera® app enhances the user experience by providing real-time data insights and guided tutorials.
Financial Overview: As of the latest updates, Nu Skin’s projected 2023 revenue is between $1.92 and $1.96 billion, with an expected EPS of $(0.10) to $0.05 or adjusted EPS of $1.62 to $1.77, excluding significant charges. The company’s strategic initiatives, including cost management and product portfolio optimization, aim to drive future growth and profitability.
Nu Skin Enterprises (NYSE: NUS) announced the resignation of CFO Mark Lawrence, effective March 31, 2023, to pursue other opportunities. Lawrence will continue as a senior advisor until April 2023 to ensure a smooth transition. The board has appointed James D. Thomas, previously the chief accounting officer, as interim CFO while searching for a permanent replacement. The company reaffirmed its first-quarter and annual guidance for 2023, initially provided on February 15, 2023. Nu Skin will release its Q1 results on May 3, 2023, followed by a conference call with investors.
Nu Skin Enterprises, Inc. (NYSE: NUS) reported Q4 2022 revenue of $522.3 million, down 22% year-over-year, impacted by foreign exchange (FX) losses of $51 million. EPS for the quarter was $1.15, improving from a loss of $(0.18) in Q4 2021. For FY 2022, revenue totaled $2.23 billion, down 17%. Looking ahead, Q1 2023 revenue is projected between $450 to $490 million, a decline of 26% to 19%. Annual revenue guidance for 2023 ranges from $2.03 billion to $2.18 billion. The company anticipates ongoing macroeconomic challenges but remains optimistic about its long-term strategy and growth prospects.